Clinical Trial Update: TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing TaxoteRe plus cisplatin versus AlImta plus cisplatin in first-line non-squamous non-small cell lung cancer was terminated. The update …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Taxotere (docetaxel)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Carcinoma, Non Small Cell Lung | Phase 3 | Status: TERMINATED